Morab-202-G000-201- A Phase II Study Of Ipilimumab, Cabozantinib, And Nivolumab In Rare Genitourinary Cancers (Iconic)
Posted Date: Dec 17, 2020
- Investigator: Amanda Jackson
- Specialties: Breast Cancer, Cancer, Gynecologic Oncology, Lung Cancer, Oncology, Ovarian Cancer
- Type of Study: Drug
This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that have spread to other places in the body. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Criteria:
To Be Eligible: Pt Must Have Diagnosis Of Triple-Negative Breast Cancer [Tnbc], Endometrial And Ovarian Cancer, Nsclc Or Adenocarcinomas, Ecog 0-1, Measurable Disease, Life Expectancy >3 Months, No Other Malignancy Within 2 Years, No Intolerance To Any C
Keywords:
Genitourinary Cancers, Rare Gu Cancer
For More Information:
University Of Cincinnati Cancer Center
513-584-7698
cancer@uchealth.com